NEOVAXSYN INC — Department of Health and Human Services SBIR Phase I: 77
NEOVAXSYN INC — SBIR Phase I award from Department of Health and Human Services.
Phase I SBIR feasibility signal
- Phase I awards fund proof-of-concept work. For capture teams, they mark early interest from Department of Health and Human Services in a technical approach.
- Watch for Phase II follow-ons from the same firm/topic family — that conversion path is where budgets and transition pressure rise.
- Obligated amount $300,000. Cross-check similar awards in the same agency and technology tags for going-rate context.
- Topic code 77 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $300,000
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Topic
- 77
- Solicitation
- PHS2020-1
- NAICS
- —
- Place of performance
- IA
- Period
- —
Description
Particle-based Co-delivery of HIV immunogens as Next-generation HIV Vaccines: Tailored immunogens (such as Envs, monomers, native and/or native-like trimers, nucleic acids/RNA such as mRNAs, self-amplifying RNAs) combined with an effective multivalent antigenic display on nanoparticles for delivery may provide a strategy to promote strong and long-lived neutralizing antibody responses against HIV and direct affinity maturation toward HIV neutralizing antibodies. The objective of this contract is to develop, evaluate, and optimize nanoparticle-based platforms to elicit broadly neutralizing antibodies against the membrane proximal external region (MPER) of the HIV-1 gp41 protein.